Cover Image
市場調查報告書

預防用人類用疫苗的全球市場

Prophylactic Human Vaccines

出版商 Global Industry Analysts, Inc. 商品編碼 236754
出版日期 內容資訊 英文 358 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
預防用人類用疫苗的全球市場 Prophylactic Human Vaccines
出版日期: 2016年07月01日 內容資訊: 英文 358 Pages
簡介

本報告提供全球預防用人類用疫苗市場相關調查,彙整市場趨勢與到2022年前的預測,各地區趨勢,參與企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 市場概要與預測
    • 人類用疫苗:序論
    • 人類用疫苗市場:概要
    • 市場趨勢
    • 促進成長要素
    • 已開發國家
    • 新興市場
    • 疫苗價格
  • 市場趨勢與課題
    • 預防用兒童用疫苗:成熟市場
    • 新興國家對兒童疫苗廠商來說是一大機會
    • 感染疾病的發病率上升加速抗感染疫苗的成長
    • 新興感染疾病的新型疫苗
    • 茲卡病毒的疫苗開發 其他
  • 競爭環境
  • 產品概要
    • 免疫的概念相關簡介
    • 在強化免疫系統上,疫苗所扮演的角色
    • 疫苗和免疫療法
    • 疫苗的歷史概要 其他
  • 疫苗市場上臨床實驗
  • 產品上市/認證
  • 近幾年的產業活動
  • 參與企業
    • ALK - Abello A/S
    • Altimmune, Inc.
    • Bavarian Nordic A/S
    • BiondVax Pharmaceuticals Ltd.
    • Bharat Biotech International Limited
    • GlaxoSmithKline Plc.
    • Hualan Biological Engineering Inc.
    • Janssen Pharmaceuticals, Inc.
    • MedImmune
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi Pasteur SA
    • Serum Institute of India Pvt. Ltd.
    • Shanghai BravoBio Co., Ltd.
    • Seqirus
    • SK Chemicals Co., Ltd.
    • T武田藥品工業
    • Zydus Cadila
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1176

This report analyzes the worldwide markets for Prophylactic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 63 companies including many key and niche players such as -

ALK Abello A/S
Altimmune, Inc.
Bavarian Nordic A/S
BiondVax Pharmaceuticals Ltd.
Bharat Biotech International Limited

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prophylactic Vaccines

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & OUTLOOK

  • Human Vaccines: A Prelude
  • Human Vaccines Market - A Snapshot
  • Market Dynamics
  • Growth Drivers in a Capsule
  • Developed World: The Key Markets
  • Emerging Markets: The Future Growth Area
  • Vaccine Pricing: The Developed - Developing Divide

2. MARKET TRENDS & ISSUES

  • Prophylactic Pediatric Vaccines - A Mature Market
  • Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers
  • Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines
  • Novel Vaccines against Emerging Infectious Diseases
  • Ongoing Developments for a Vaccine against Zika Virus
  • Sanofi's Dengue Vaccine First-to-Market
    • Pipeline & Marketed Dengue Vaccine: 2016
  • Computational Tools Come to Aid in Development of Ebola Vaccines
  • Vaccine for AIDS
    • Ongoing Research for HIV Vaccine & Commercial Pipeline
      • List of Clinical Trial (Phase II) AIDS Vaccines: 2015
    • Staggering Global Statistics of AIDS - Opportunity Indicator
    • Table 1: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart)
    • Table 2: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart)
    • Table 3: Worldwide AIDS related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart)
    • Table 4: HIV-Positive Individuals, by Gender (2014): Percentage Breakdown of Women and Men Tested HIV-Positive in all WHO Regions (includes corresponding Graph/Chart)
  • Vaccination-Autism Link and Other Safety Concerns Thwarted
  • Threat of Pandemic Rejuvenates Vaccine Market
  • Influenza Vaccines on a Growing Spree
  • Influenza Vaccines on the Current Market: 2016
  • H1N1 Vaccines Hit the Market in August 2009
    • H1N1 Influenza Vaccines and Manufacturers
  • Influenza Market Faces Several Challenges
  • Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
  • Unmet Demand for TB Vaccine
  • Key TB Vaccine Candidates in the Pipeline: 2016
  • Need for a Human Vaccine for Leishmaniasis
  • Economic Factors Hamper Optimal Vaccine Development and Delivery
  • Increasing Need for Vaccine Promotion in the Developing Regions
  • Changing Vaccine Needs
  • Religious Concerns over Immunizing Young Girls against Human Papillomavirus
  • Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
  • DNA Vaccines: Engineering Growth
  • Noninjectable Vaccines: Gain without Pain
  • Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
  • Conjugate Vaccines: A Technological Innovation
  • Hib Vaccines on the Market: 2016
  • Growing Pricing Pressure - A Major Market Deterrent
  • Safety Issues Come to the Fore
  • BioWarfare: Threat Perception and Preparedness
  • Overview of Potential Bio-Terrorist Agents
  • Smallpox (Variola Major)
  • Anthrax (Bacillus Anthracis)
  • Plague (Yersinia Pestis)
  • Botulism (Clostridium Botulinum)
  • Tularemia (Francisella Tularensis)
  • Tackling Cold Chain Issues
  • Trade Statistics
    • Table 5: Global Exports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart)
    • Table 6: Global Imports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart)

3. COMPETITIVE LANDSCAPE

  • Competitive Scenario
  • Leading Players
    • Table 7: Leading Players in the Global Human Vaccines Market (2015): Annual Sales in US$ Million for GlaxoSmithKline, Merck, Pfizer and Sanofi (includes corresponding Graph/Chart)
    • Table 8: Top Five Human Vaccines Worldwide by Sales Value: 2015 (In US$ Million) (includes corresponding Graph/Chart)
  • Pfizer Scores Big with Prevnar
  • Trumenba Shows Promise in Phase III Clinical Trials
  • GSK Takes Big Leap into the Meningococcal Vaccine Market
  • Acquired Products Strengthen GSK's Vaccines Sales
  • The Potential for MenABCWY Vaccine
    • Table 9: US Meningococcal Disease Incidence by Serogroup Distribution (1990 & 2013): Percentage Breakdown of Disease Incidence for Serotypes B, C, Y and Others (includes corresponding Graph/Chart)
  • Sanofi Works on Production Issues to Boost Sales
  • New Vaccines to Enhance Prospects for Sanofi
    • Sanofi's Human Vaccine R&D Pipeline
  • Weaker Sales Drive Merck and Sanofi's European JV Split
  • Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market

4. PRODUCT OVERVIEW

  • Introduction to the Concept of Immunity
  • Role of Vaccines in Strengthening the Immune System
  • Vaccines and Immunotherapy
  • Historical Overview of Vaccines
  • How it Began
  • So Far So Good
    • Successful Vaccine Introductions in the Past
  • Contribution of Animal Research to Vaccine Production
  • Types of Vaccines
  • Live, Attenuated Vaccines
  • Combination Vaccines
  • Killed or Inactivated Vaccines
  • DNA & Recombinant DNA Vaccines
  • Toxoids
  • Cellular Fractions
  • Conjugate Vaccines
  • Subunit Vaccines
  • Passive Immunization
  • Prophylactic Vaccines
  • Prevention Better than Cure
  • Prophylactic Pediatric Vaccines
    • Vaccination over the Years
  • BCG Vaccine
    • Growth Boosting Factors for TB Vaccines
    • Demand Restraining Factors for TB Vaccines
    • Major Issues to be addressed in the TB Vaccine Market
      • Hemophilus Influenza Type B Vaccine
      • Diphtheria/Tetanus/Pertussis Vaccines
  • Hepatitis A Vaccine
  • Hepatitis B Vaccine
    • Hepatitis B Epidemiology
  • Measles/Mumps/Rubella Vaccines
  • Rotavirus Vaccines
  • Polio Vaccines
  • Varicella Vaccine
  • Combination Vaccines
  • Prophylactic Adult Vaccines
    • Hepatitis A Vaccine
    • Hepatitis B Vaccines
    • Key Issues Affecting the Adult Hepatitis Vaccines Market
  • Cholera Vaccine
  • Japanese Encephalitis Vaccines
  • Influenza Vaccines
    • Influenza A Virus
    • Influenza A (H1N1) Virus
    • Vaccine Virus Selection for the 2015-2016 Influenza Season
      • WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016
      • WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016
  • Lyme Disease Vaccine
  • Pneumococcal Disease Vaccines
  • Meningococcal Vaccines
  • Rabies Vaccines
  • Typhoid Vaccine
  • Yellow Fever Vaccine
  • Mechanisms for Vaccine Delivery
  • Edible Vaccines
  • Oral Vaccines
  • Tablet Based Vaccines
  • Mucosal Delivery
  • Transdermal Patch Delivery
  • Storage Problems
  • Perfluorocarbons as Alternative to Overcome Storage Problems
  • Costs
  • Standards for Vaccine Safety and Quality

5. CLINICAL TRIALS IN THE VACCINES MARKET

  • Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
  • Takeda Begins Phase2b Trial for World's First Norovirus Vaccine
  • Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine
  • Investigational Vaccine for P.vivax Malaria Enters Human Trials
  • Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile
  • Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine
  • Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine
  • Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies
  • Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

6. PRODUCT LAUNCHES/APPROVALS

  • FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok
  • Sanofi's Dengue Vaccine Approved in Costa Rica
  • GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line
  • FDA Approves Seqirus' FLUCELVAX QUADRIVALENT(tm) Influenza Vaccine
  • China Launches HFMD Vaccine
  • Bharat Biotech Introduces ZIKAVAC(r) Vaccine for Zika Infection
  • Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
  • WHO Accepts Merck's Investigational Ebola Vaccine Application for Review
  • Sanofi's Dengvaxia(r) Receives Marketing Authorization in Mexico
  • SK Chemicals Launches Influenza Vaccine SKYCellflu
  • Sanofi Pasteur Ships First Doses of Fluzone(r) for the US Market
  • Bharat Biotech Launches Made-in-India ROTAVAC(r) Vaccine
  • FDA Approves Sanofi's sBLA for Fluzone Vaccine
  • FDA Approves Merck's HPV Vaccine GARDASIL(r)9
  • Sanofi Pasteur Launches Shan5(tm) Vaccine Developed by its Affiliate Shantha
  • US FDA Approves First Meningococcal Disease Vaccine Trumenba

7. RECENT INDUSTRY ACTIVITY

  • WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13
  • Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility
  • Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
  • Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines
  • WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue
  • Kaketsuken to Sell Vaccines Business to Astellas
  • Sanofi and Merck End Joint Venture on Vaccines
  • GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
  • Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA
  • Bavarian Nordic Enters into License Agreement with Janssen
  • CSL Rebrands Influenza Vaccines Business as Seqirus
  • MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D
  • GlaxoSmithKline Acquires Novartis' Vaccines Business
  • Vaxin Changes Name to Altimmune
  • Takeda Expands Commercialization Agreement with Nanotherapeutics
  • MedImmune Enters Into License Agreement with Inovio Pharmaceuticals
  • CSL Completes Acquisition of Novartis' Influenza Vaccines Business
  • Pfizer to Acquire Meningitis Vaccines from GSK
  • Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License
  • Takeda Transfers HPV Vaccine License Agreement to Kaketsuken
  • GlaxoSmithKline Acquires GlycoVaxyn
  • Pfizer Acquires Redvax GmbH
  • Pfizer Acquires Baxter's Vaccines and Portion of Manufacturing Facility

8. FOCUS ON SELECT PLAYERS

  • ALK - Abello A/S (Denmark)
  • Altimmune, Inc. (US)
  • Bavarian Nordic A/S (Denmark)
  • BiondVax Pharmaceuticals Ltd. (Israel)
  • Bharat Biotech International Limited (India)
  • GlaxoSmithKline Plc. (UK)
  • Hualan Biological Engineering Inc. (China)
  • Janssen Pharmaceuticals, Inc. (US)
  • MedImmune (US)
  • Merck & Co., Inc. (US)
  • Pfizer Inc. (US)
  • Sanofi Pasteur SA (France)
  • Serum Institute of India Pvt. Ltd. (India)
  • Shanghai BravoBio Co., Ltd. (China)
  • Seqirus (UK)
  • SK Chemicals Co., Ltd. (Korea)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Zydus Cadila (India)

9. GLOBAL MARKET PERSPECTIVE

    • Table 10: World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines Prophylactic by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Prophylactic Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 12: World 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 15: World 14-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
      • Key Growth Drivers
      • Select Market Constraints
    • Major Trends in the US Vaccines Development
      • Increasing Consolidation Activity among Companies
      • Combination Vaccines and New Delivery Models Gaining Traction
      • Protests against Vaccination Make Companies More Cautious
      • Technological Challenges in the Development of RSV Vaccines
    • Pediatric Vaccines Market
      • Improved Pricing Scenario for Pediatric Vaccines
      • Market Focus Shifting from Pediatric Vaccines
      • Growth Drivers for US Pediatric Vaccines Market
      • Demand Restraining Factors for US Pediatric Vaccines Market
    • Opportunity Indicators
    • Table 19: Number of Reported Cases for Vaccine-Preventable Diseases in American Regions: 2009-2013
    • Table 20: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)
    • The US Influenza Vaccine Market
      • 'Swine Flu' Strain Returns in the 2013-14 Season
    • Table 21: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016
    • Table 22: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016
      • A Background on the Need for Flu Vaccines
    • Need for Immunization Schedule for Adults
      • Vaccines and Intended User Group
      • Adult Population: To Drive Future Growth of Pertussis Vaccines Market
    • Table 23: Pertussis Cases (In Thousands) for Years 2000 through 2014 (includes corresponding Graph/Chart)
    • Vaccine Pricing in the US
    • Regulatory Environment
      • Review Process Make Vaccines Safer
    • Imports-Exports Scenario
    • Table 24: US Exports of Human Vaccines by Country (2014 & 2015) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)
    • Table 25: US Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)
    • Clinical Trials
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 26: US Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: US Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 28: US 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Opposition to CMA's Mandatory Vaccination Program
    • 2009 H1N1 Pandemic Boosts Vaccines Sales
    • Trade Statistics
    • Table 29: Canadian Exports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)
    • Table 30: Canadian Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 31: Canadian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 32: Canadian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 33: Canadian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Controversy, Confusion and Hasty Actions Marr HPV Vaccination Market
    • Strategic Corporate Developments
    • Key Japan-based Player - Takeda Pharmaceutical Company Limited
  • B. Market Analytics
    • Table 34: Japanese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: Japanese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 36: Japanese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Vaccine Pricing in Europe
    • Major Drawbacks
    • Regulatory Mechanism for Vaccines in Europe
    • An Insight into European Influenza Vaccination Scenario
      • H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation
      • Cell-based Vaccine Production Remains Nascent, Egg-based widely used
      • EU Welcomes Quadrivalent LAIVs
      • Major Influenza Vaccines Available in European Union Member Countries
      • Major H1N1 Flu Vaccines Available in Select East European Markets
  • B. Market Analytics
    • Table 37: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: European Historic Review for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 39: European 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 40: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: European Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 42: European 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Clinical Trial
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 43: French Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 44: French Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 45: French 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • Market Analysis
    • Table 46: German Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 47: German Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 48: German 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 49: Italian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: Italian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 51: Italian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Product Launch
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 52: UK Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 53: UK Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 54: UK 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 55: Spanish Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 56: Spanish Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 57: Spanish 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 58: Russian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 59: Russian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 60: Russian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Clinical Trial
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 61: Rest of Europe Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 62: Rest of Europe Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 63: Rest of Europe 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Asian Vaccine Industry
    • Challenges
    • 2014-15: Deadliest Swine Flu Season in India Since 2009
      • Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets
  • B. Market Analytics
    • Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 65: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 66: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 67: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 68: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 69: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Outlook
    • Large Population Offers High Potential
    • Growth Drivers
    • China - A Lucrative yet Difficult to Permeate Market
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 70: Chinese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 71: Chinese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 72: Chinese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • Current & Future Analysis
    • Market Overview
    • Hepatitis B Vaccine in India
    • Combination Vaccines
      • Indian Vaccine Market - Select Combination Vaccines Available in the Country
    • The Patent Act (Third Amendment), 2005
    • Product Launches
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 73: Indian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 74: Indian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 75: Indian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Malaysia - Stricken by Vaccine Shortage
    • Product Launches
    • Strategic Corporate Developments
    • Key Korea-based Player - SK Chemicals Co., Ltd.
  • B. Market Analytics
    • Table 76: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 77: Rest of Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 78: Rest of Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 79: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 80: Latin American Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 81: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 82: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 83: Latin American Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 84: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6a. BRAZIL

  • Market Analysis
    • Table 85: Brazilian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 86: Brazilian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 87: Brazilian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA

  • A. Market Analysis
    • Outlook
    • Product Launches
  • B. Market Analytics
    • Table 88: Rest of Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 89: Rest of Latin American Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 90: Rest of Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Nigeria: A Severely Underserved Market
    • Table 91: Deaths in Nigerian Children Under Five Years by Cause (2015): Percentage Breakdown of Number of Deaths due to Diarrhoea, Malaria, Measles, Neonatal, Pneumonia, and Others (includes corresponding Graph/Chart)
    • BiondVax Pharmaceuticals Ltd. - A Key Israel-based Player
  • B. Market Analytics
    • Table 92: Rest of World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 93: Rest of World Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 94: Rest of World 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top